Table 9.
Ex vivo permeation parameters of bromocriptine mesylate–polycaprolactone nanoparticles (BM-PCL NPs) and bromocriptine mesylate–chitosan–polycaprolactone nanoparticles (BM-CS-PCL NPs).
| Formulations | BM Permeated | J (µg/cm2/h) | Kp × 10−4 (cm h−1) | ER |
|---|---|---|---|---|
| BM-PCL NPs | 22.29 ± 1.45 | 3.56 ± 0.18 | 35.54 ± 2.44 | - |
| BM-CS-PCL NPs 0.25% | 48.65 ± 3.04 | 14.61 ± 2.23 | 147.59 ± 22.52 | 2.18 |
| BM-CS-PCL NPs 0.5% | 41.05 ± 2.01 | 7.34 ± 0.63 | 74.66 ± 8.07 | 1.84 |
| BM-CS-PCL NPs 1% | 38.99 ± 1.47 | 6.52 ± 0.53 | 65.98 ± 6.98 | 1.75 |
ER: Enhancement ratio; J: Permeability flux; Kp: Permeability coefficient.